Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.
J Med Case Rep · 2014
Last updated 2026-05-28A 38-year-old woman with severe obesity and type 2 diabetes took a GLP-1 receptor agonist (along with metformin and diet changes) for 14 months before planned weight-loss surgery. Her blood sugar control improved (hemoglobin A1c dropped from 7.4% to 5.5%), and she lost 21.2 kg (about 47 pounds) during that time.
AI summary of the abstract below.
| Journal | J Med Case Rep, 2014 |
|---|---|
| Citations | 1 |
| Relative citation ratio | 0.06 |
| NIH percentile | 5 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
INTRODUCTION: Glucagon-like peptide-1 receptor agonists, a new class of anti-diabetic drugs, are widely used in the treatment of type 2 diabetes. However, the effect of glucagon-like peptide-1 receptor agonists on the treatment of preoperative weight loss in obese type 2 diabetic patients has not been reported.
CASE PRESENTATION: A 38-year-old Taiwanese woman presented to our hospital with morbid obesity and type 2 diabetes mellitus. Bariatric surgery was recommended by a general surgery specialist. Weight loss before surgery was recommended to reduce the frequency of surgical complications. In addition to diet control with lifestyle modifications, pharmacological treatment with metformin and glucagon-like peptide-1 receptor agonists was administered. Fourteen months of treatment reduced her hemoglobin A1c level from 7.4 to 5.5% and reduced her body weight by 21.2 kg.
CONCLUSIONS: One year of diet control with lifestyle modifications and pharmacological treatment with glucagon-like peptide-1 receptor agonists and metformin markedly decreased hemoglobin A1c levels and resulted in effective and substantial weight loss in a morbidly obese patient with dysregulated diabetes during the preoperative period.
Verbatim abstract via PubMed 25213589 ↗